Disclaimer: This site is intended for residents of the United States only. If you live outside of the US, for information on studies of olaparib in ovarian cancer please visit www.astrazenecaclinicaltrials.com and enter ‘olaparib’ in the search box.
Ovarian cancer is the ninth most common cancer in women (excluding non-melanoma skin cancers). During their lifetime, one out of 75 women will get cancer of the ovaries and it is the fifth most common cause of death from cancer in women.
Currently, there are five different treatment options for ovarian cancer:
- Hormone therapy
- Targeted therapy
- Radiation therapy
with two or more different treatment types often being used.
In approximately 80% of women, the disease will come back after their first treatment with chemotherapy. Scientists are still searching for new treatments to help fight this disease.
AstraZeneca is committed to ovarian cancer research to help find effective treatments for this disease. This website provides information about the new SOLO3 study (also known as a clinical trial) for patients who may be interested in taking part, as well as information for their families, caregivers, and healthcare professionals. The goal of the SOLO3 study is to determine if a new medicine (otherwise known as an ‘investigational therapy’) called olaparib could be a successful treatment for a specific type of ovarian cancer. Olaparib has already been approved by the Food and Drug Administration (FDA) for the treatment of women with inherited BRCA mutations with advanced ovarian cancer, who have previously received three or more courses of chemotherapy .
We have previously recruited for two ovarian cancer studies called SOLO1 and SOLO2, involving women around the world with BRCA-mutated ovarian cancer. The SOLO1 clinical trial involves women with newly diagnosed ovarian cancer, whereas the SOLO2 clinical trial includes patients who have previously been diagnosed and treated for ovarian cancer and where the disease has come back; this is termed ‘relapsed’ or ‘recurrent’ ovarian cancer. Recruitment for the SOLO1 and SOLO2 studies is now closed due to the maximum number of patients in each study being reached.
We have recently started a new ovarian cancer study called SOLO3, involving women around the world with relapsed/recurrent ovarian cancer, who carry an inherited BRCA mutation.